A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Conditions

• Lichen Planopilaris

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Oral Brepocitinib — DRUG
  Oral
• Placebo — DRUG
  Oral

Study Details

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Key Dates

First listed

Apr 16, 2026

Start date

Mar 19, 2026

Status verified

Jul 2026

Primary completion

Dec 31, 2028

Completion

Jul 31, 2029

Study Design

Enrollment

342 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Brepocitinib Dose Level 1
• Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24 [ Time Frame: Week 24 ]

Central Contacts

• Clinical Trial Administrator
  (212) 634-9743
  [email protected]

Locations (47)

Find similar trials in Birmingham, AL

Related Studies

• Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
  PHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York